Embattled Valeant Pharma reports 3Q loss, slashes guidance

Former Wall Street darling Valeant Pharmaceuticals International Inc., now more of a dog for its reviled strategy of huge drug price hikes, posted dismal third-quarter results and sharply reduced its profit forecast for 2016, driving down its stock price.